

Financial news for SAGE dated on 2020-05-26: Sage Therapeutics shares are trading higher after RBC Capital reiterates an Outperform and raised the price target from \$72 to \$75 per share.

Financial news for SAGE dated on 2020-05-26: RBC Capital Reiterates Outperform on Sage Therapeutics, Raises Price Target to \$75

Financial news for SAGE dated on 2020-05-08: Wedbush Downgrades Sage Therapeutics to Neutral, Raises Price Target of \$37

Financial news for SAGE dated on 2020-05-08: SunTrust Robinson Humphrey Maintains Hold on Sage Therapeutics, Lowers Price Target to \$35

Financial news for SAGE dated on 2020-05-08: RBC Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to \$72

Financial news for SAGE dated on 2020-05-07: Sage Therapeutics Q1 EPS \$(2.440) Beats \$(3.140) Estimate, Sales \$2.300M Miss \$2.800M Estimate

Financial news for SAGE dated on 2020-04-28: RBC Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to \$71

Financial news for SAGE dated on 2020-04-09: SunTrust Robinson Humphrey Maintains Hold on Sage Therapeutics, Lowers Price Target to \$37

Financial news for SAGE dated on 2020-04-09: BMO Capital Maintains Outperform on Sage Therapeutics, Lowers Price Target to \$65

Financial news for SAGE dated on 2020-04-08: Canaccord Genuity Maintains Buy on Sage Therapeutics, Lowers Price Target to \$80

Financial news for SAGE dated on 2020-04-08: Citigroup Maintains Buy on Sage Therapeutics, Raises Price Target to \$54

Financial news for SAGE dated on 2020-04-08: RBC Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to \$68

Financial news for SAGE dated on 2020-04-08: Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to \$36

Financial news for SAGE dated on 2020-04-08: Oppenheimer Maintains Outperform on Sage Therapeutics, Lowers Price Target to \$50

Financial news for SAGE dated on 2020-04-08: Guggenheim Downgrades Sage Therapeutics to Neutral

Financial news for SAGE dated on 2020-04-07: Sage Says Current Cash Balance, Marketable Securities Should Support Operations Into 2022

Financial news for SAGE dated on 2020-04-07: Sage Therapeutics Reports Restructuring, Sees Annualized Cost Savings ~\$170M, Will Cut 340 Employees From Headcount, ~53% Of Workforce

Financial news for SAGE dated on 2020-03-26: SunTrust Robinson Humphrey Maintains Hold on Sage Therapeutics, Lowers Price Target to \$40

Financial news for SAGE dated on 2020-03-18: Sage Therapeutics Announces Development Plan For Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting With FDA

Financial news for SAGE dated on 2020-03-18: RBC Capital Upgrades Sage Therapeutics to Outperform, Lowers Price Target to \$60

Financial news for SAGE dated on 2020-03-06: Citigroup Initiates Coverage On Sage Therapeutics with Buy Rating, Announces \$71 Price Target

Financial news for SAGE dated on 2020-03-03: Morgan Stanley Maintains Overweight on Sage Therapeutics, Lowers Price Target to \$117

Financial news for SAGE dated on 2020-02-28: SunTrust Robinson Humphrey Maintains Hold on Sage Therapeutics, Lowers Price Target to \$50

Financial news for SAGE dated on 2020-02-28: H.C. Wainwright Maintains Neutral on Sage Therapeutics, Lowers Price Target to \$78

Financial news for SAGE dated on 2020-02-28: Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to \$58

Financial news for SAGE dated on 2020-02-27: Sage Therapeutics shares are trading

lower after the company reported worse-than-expected Q4 sales results.

Financial news for SAGE dated on 2020-02-27: Sage Therapeutics Sees ZULRESSO Sales Growth 'Modest' Over Next Couple Qtrs., Sees Growth In Sales During H2'20

Financial news for SAGE dated on 2020-02-27: Sage Therapeutics Q4 EPS \$(3.25) Beats \$(3.61) Estimate, Sales \$1.96M Miss \$3.68M Estimate

Financial news for SAGE dated on 2020-02-06: Mizuho Initiates Coverage On Sage Therapeutics with Neutral Rating, Announces \$69 Price Target

Financial news for SAGE dated on 2020-02-05: Mizuho Initiates Coverage On Pfizer, Evolus, Karuna Therapeutics With Buy Ratings, Neurocrine Biosciences, Sage Therapeutics With Neutrals

Financial news for SAGE dated on 2019-12-23: Watching Sage Therapeutics Shares As Traders Circulate Notice From ClinicalTrials.gov Showing Recruitment Status For Co.'s SAGE-217 Treatment For Major Depressive Disorder Suspended

Financial news for SAGE dated on 2019-12-10: Sage Therapeutics Says Plans To Advance SAGE-718 For Huntington's Disease

Financial news for SAGE dated on 2019-12-06: SunTrust Robinson Humphrey Downgrades Sage Therapeutics to Hold, Lowers Price Target to \$70

Financial news for SAGE dated on 2019-12-06: Ladenburg Thalmann Downgrades Sage Therapeutics to Neutral

Financial news for SAGE dated on 2019-12-06: JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to \$105

Financial news for SAGE dated on 2019-12-06: Morgan Stanley Maintains Overweight on Sage Therapeutics, Lowers Price Target to \$125

Financial news for SAGE dated on 2019-12-06: Sage Therapeutics shares are trading higher after SVB Leerink upgraded the stock from Underperform to Market Perform.

Financial news for SAGE dated on 2019-12-06: SVB Leerink Upgrades Sage Therapeutics to Market Perform

Financial news for SAGE dated on 2019-12-05: Hearing Suntrust Downgraded Sage Therapeutics To Hold; Unconfirmed

Financial news for SAGE dated on 2019-12-05: Sage Therapeutics Shares Resume Trade, Down 56%

Financial news for SAGE dated on 2019-12-05: Sage Therapeutics shares trading lower following news topline results from a Phase 3 study of SAGE-217 did not meet a primary endpoint at day 15 of the trial.

Financial news for SAGE dated on 2019-12-05: Sage Therapeutics Reports Topline Results From Pivotal Phase 3 MOUNTAIN Study Of SAGE-217 In Major Depressive Disorder Did Not Meet Primary Endpoint At Day 15

Financial news for SAGE dated on 2019-11-13: Canaccord Genuity Maintains Buy on Sage Therapeutics, Lowers Price Target to \$218

Financial news for SAGE dated on 2019-11-12: Sage Therapeutics Q3 EPS \$(3.48) Misses \$(3.36) Estimate, Sales \$3.57M Miss \$3.6M Estimate

Financial news for SAGE dated on 2019-10-30: H.C. Wainwright Initiates Coverage On Sage Therapeutics with Neutral Rating, Announces \$160 Price Target

Financial news for SAGE dated on 2019-09-04: Sage Therapeutics Highlights New England Journal Of Medicine Published Data From Phase 2 Trial With SAGE-217 For Major Depressive Disorder

Financial news for SAGE dated on 2019-08-06: Sage Therapeutics Q2 EPS \$(3.28) Beats \$(3.33) Estimate

Financial news for SAGE dated on 2019-07-24: UPDATE: Sage Says 'Data from Phase 1 study with SAGE-324 show activity in essential tremor; differentiated profile opens potential pathways for development in additional neurological indications'

Financial news for SAGE dated on 2019-07-24: Sage Therapeutics Reports Data From Phase 2 Open-Label Study Of SAGE-217 For Bipolar Depression Showed 'demonstrate rapid improvement compared to baseline'

Financial news for SAGE dated on 2019-07-09: Sage Therapeutics shares are trading

higher after Stifel reiterated a Buy rating and said they expect SAGE-217 to show signs of efficacy in bipolar depression. Analysts said the upcoming July pipeline update may represent an 'incremental positive.'

Financial news for SAGE dated on 2019-07-01: Ligand Pharmaceuticals Highlights Launch Of Sage Therapeutics' ZULRESSO, Which Utilizes Ligand's Captisol

Financial news for SAGE dated on 2019-06-14: Sage Therapeutics Announces US Drug Enforcement Administration Scheduling of ZULRESSO Injection ; On Track For Full US Commercial Launch In Late June

Financial news for SAGE dated on 2019-05-23: Wedbush Initiates Coverage On Sage Therapeutics, Inc. - Common Stock with Outperform Rating, Announces \$207 Price Target

Financial news for SAGE dated on 2019-04-26: Raymond James Reinstates Market Perform on Sage Therapeutics, Inc. - Common Stock

Financial news for SAGE dated on 2019-04-25: Jefferies Initiates Coverage On Sage Therapeutics, Inc. - Common Stock with Buy Rating, Announces \$195 Price Target

Financial news for SAGE dated on 2019-04-25: Jefferies Initiates Coverage On Sage Therapeutics, Inc. - Common Stock with Buy Rating

Financial news for SAGE dated on 2019-04-04: Hearing Dealreporter Says Biogen May Be Targeting Sage Therapeutics

Financial news for SAGE dated on 2019-04-01: Alkermes, Merck, Sage Therapeutics and Takeda Pharma Announce a Partnership to Qualify Biomarkers for Schizophrenia Drug Development

Financial news for SAGE dated on 2019-03-21: Ligand Pharma Reports Will Receive \$3M Milestone Payment Related To FDA Approval Of Sage Therapeutics' ZULRESSO Injection For Treatment Of PPD

Financial news for SAGE dated on 2019-02-26: Sage Therapeutics Earlier Announced Pricing Of \$500M Common Stock Offering At \$150/Share

Financial news for SAGE dated on 2019-02-26: Sage Therapeutics shares are trading lower after the company announced a \$500 million stock offering priced at \$150 per share.

Financial news for SAGE dated on 2019-02-25: Sage Therapeutics shares are trading lower after the company announced a \$500 million common stock offering.

Financial news for SAGE dated on 2019-02-25: Sage Therapeutics Reports Offering OF \$500M Common Stock Offering

Financial news for SAGE dated on 2019-02-22: Guggenheim Initiates Coverage On Sage Therapeutics with Buy Rating, Announces \$205 Price Target

Financial news for SAGE dated on 2019-02-19: Sage Therapeutics Q4 EPS \$(3.38) Misses \$(2.91) Estimate, Sales \$273K

Financial news for SAGE dated on 2019-01-08: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Tue., Jan. 8, 2019

Financial news for SAGE dated on 2019-01-07: Sage Therapeutics' shares are trading higher after SAGE-217 met its primary and secondary endpoints in its Phase 3 clinical trial for postpartum depression.

Financial news for SAGE dated on 2019-01-07: Sage Therapeutics' SAGE-217 Met its Primary and Secondary Endpoints in its Phase 3 Clinical Trial in Postpartum Depression

Financial news for SAGE dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for SAGE dated on 2018-12-19: Morgan Stanley Maintains Overweight on Sage Therapeutics, Lowers Price Target to \$213

Financial news for SAGE dated on 2018-12-18: Sage Therapeutics Filing Shows Registration For Mixed Securities Offering, No Size Disclosed

Financial news for SAGE dated on 2018-12-10: Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018

Financial news for SAGE dated on 2018-11-20: Sage Therapeutics Reports Received Notification Of PDUFA Extension For ZULRESSO Injection From Dec. 19, 2018 To Mar. 19, 2019

Financial news for SAGE dated on 2018-11-15: Leerink Swann Initiates Coverage On Sage Therapeutics with Underperform Rating, Announces \$80 Price Target

Financial news for SAGE dated on 2018-11-13: Leerink Swann Initiates Coverage On Sage Therapeutics with Underperform Rating, Announces \$80 Price Target

Financial news for SAGE dated on 2018-11-06: Sage Therapeutics Q3 EPS \$(2.63) Misses \$(2.42) Estimate

Financial news for SAGE dated on 2018-11-05: RBC Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to \$261

Financial news for SAGE dated on 2018-11-05: Canaccord Reiterates Buy, \$220 Price Target On Sage Therapeutics; Says Phase 3 Top-Line Data For Oral SAGE-217 In Postpartum Depression Will Serve As A Big Catalyst In Q4

Financial news for SAGE dated on 2018-11-02: Sage Therapeutics Press Release Confirms FDA AdCom Meeting Votes 17-1 In Support Of ZULRESSO (Brexanolone)'s Safety

Financial news for SAGE dated on 2018-11-02: US FDA Panel Votes In Favor Of Sage Therapeutics' Treatment For Postpartum Depression, Says Benefits Of Drug Outweigh Risks

Financial news for SAGE dated on 2018-11-02: Hearing AdCom Panel Voted 16-2 In Favor Of Safety For Sage Therapeutics' ZULRESSO, Unconfirmed

Financial news for SAGE dated on 2018-11-02: Sage Therapeutics Reports Shares Halted For AdCom Meeting On ZULRESSO Injection For Treatment Of Postpartum Depression; BZ NOTE: Expect Sage Shares To Be Halted For Most Of Friday's Intraday Session

Financial news for SAGE dated on 2018-11-02: Sage Therapeutics Shares Halted News Pending

Financial news for SAGE dated on 2018-10-11: Morgan Stanley Maintains Overweight on Sage Therapeutics, Raises Price Target to \$230

Financial news for SAGE dated on 2018-10-10: Hearing Oppenheimer Initiated Sage Therapeutics With Outperform Rating, \$170 Price Target

Financial news for SAGE dated on 2018-08-07: Stifel Transfers Coverage Of Sage Therapeutics With A Buy And \$239 Price Target

Financial news for SAGE dated on 2018-08-07: Sage Therapeutics Q2 EPS \$(0.36) Beats \$(1.89) Estimate, Sales \$90M

Financial news for SAGE dated on 2018-08-06: PiperJaffray Initiates Coverage On Sage Therapeutics with Overweight Rating, Announces \$206 Price Target

Financial news for SAGE dated on 2018-07-13: Morgan Stanley Maintains Overweight on Sage Therapeutics, Raises Price Target to \$228

Financial news for SAGE dated on 2018-06-13: Sage Therapeutics, Shionogi Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan, S. Korea

Financial news for SAGE dated on 2018-06-13: Canaccord Genuity Maintains Buy on Sage Therapeutics, Raises Price Target to \$220

Financial news for SAGE dated on 2018-06-12: Sage Announces Pivotal Phase 3 Trial Status For SAGE-217 in Major Depressive Disorder And Postpartum Depression Based On FDA Breakthrough Therapy Meeting

Financial news for SAGE dated on 2018-06-06: Ladenburg Thalmann Initiates Coverage On Sage Therapeutics with Buy Rating, Announces \$230 Price Target

Financial news for SAGE dated on 2018-05-03: Sage Therapeutics Q1 EPS \$(1.68) Beats \$(1.84) Estimate

Financial news for SAGE dated on 2018-04-23: Sage Therapeutics Submits New Drug Application to the US FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression

Financial news for SAGE dated on 2018-04-10: '\$SAGE spox to me: "Yes, we cancelled participation in the JPMorgan meeting in Napa due to some travel logistics issues - just flight schedule complications."' -STAT's Adam Feuerstein

Financial news for SAGE dated on 2018-04-10: Traders Circulating Social Media Chatter That Sage Therapeutics Cancelled Out Of Upcoming Conference Due To A Scheduling

Conflict

Financial news for SAGE dated on 2018-04-10: UPDATE: Sage Therapeutics Shares Spike, Seeing Vague Social Media Mention Of Rumors Co. Cancelled A Conference Presentation, Unconfirmed

Financial news for SAGE dated on 2018-04-10: Sage Therapeutics Shares Up ~20%, Not Seeing Any Notable News Item Yet

Financial news for SAGE dated on 2018-02-26: Morgan Stanley Initiates Coverage On Sage Therapeutics with Overweight Rating, Announces \$225.00 Price Target

Financial news for SAGE dated on 2018-02-22: Sage Therapeutics Reports Q4 EPS \$(1.75) vs \$(1.99) Est.

Financial news for SAGE dated on 2018-02-14: Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma

Financial news for SAGE dated on 2018-02-07: Sage Therapeutics Announces \$575M Common Stock Offering

Financial news for SAGE dated on 2018-02-07: Sage Therapeutics Grated Breakthrough Designation by the FDA for SAGE-217

Financial news for SAGE dated on 2018-01-08: Sage Therapeutics To Give Pipeline Update At JPM Conf. And Outline Key Initiatives For 2018

Financial news for SAGE dated on 2018-01-08: SAGE Therapeutics Shares Down 6% Mon.; Co. Earlier Issued Release Highlighting Will Offer Update On Pipeline, Outline Key '18 Initiatives at JP Morgan Healthcare Conference

Financial news for SAGE dated on 2017-12-08: BMO Continues Sell-Side Trend Of Price Target Raise In Sage Therapeutics, Ups Target To \$203 As Firm Says Phase 2 MDD Data 'Points To SAGE-217 As Best-In Class Drug'

Financial news for SAGE dated on 2017-12-07: Cowen Raises Sage Therapeutics Price Target To \$202 On Derisked Potential In MDD

Financial news for SAGE dated on 2017-12-07: SunTrust Raises Sage Price Target From \$116 To \$178 On Positive Phase 2 Data In MDD

Financial news for SAGE dated on 2017-12-07: Marinus Pharmaceuticals Shares Up 16.64% On 2x Avg. Volume, Perhaps In Sympathy With Sage Therapeutics After It's Positive Phase 2 Results; Both Develop Neuropsychiatric Disorder Treatments

Financial news for SAGE dated on 2017-12-07: Adam Feuerstein Tweets: Jeff Jonas is doing a great job as \$SAGE CEO but let's pump the brakes a bit on naming him Best CEO.

Financial news for SAGE dated on 2017-12-07: SAGE Therapeutics Shares Up 50.4% After the Company's Phase 2 Trial Met its Primary Endpoint

Financial news for SAGE dated on 2017-12-07: Sage Therapeutics Announces Phase 2 Trial of SAGE-217 Met its Primary Endpoint

Financial news for SAGE dated on 2017-11-16: Bank of America Maintains Buy on Sage Therapeutics, Lowers Price Target to \$101.00

Financial news for SAGE dated on 2017-11-13: Sage Therapeutics Announces \$300M Offering Common Stock

Financial news for SAGE dated on 2017-11-13: Canaccord Genuity Maintains Buy on Sage Therapeutics, Raises Price Target to \$140.00

Financial news for SAGE dated on 2017-11-10: Chardan Capital Upgrades Sage Therapeutics to Buy

Financial news for SAGE dated on 2017-11-09: Adam Feuerstein Tweets: Updated: \$SAGE drug reduces postpartum depression in two late-stage clinical trials
statnews.com/2017/11/09/sag...

Financial news for SAGE dated on 2017-11-09: Adam Feuerstein Tweets: Gotta give \$SAGE CEO Jeff Jonas, his team a lot of credit. Doubters scoffed at their CNS drug development strategy but it proved out today.

Financial news for SAGE dated on 2017-11-09: Adam Feuerstein Tweets: Okay, maybe other stuff matters. \$SAGE Jonas notes brexanolone effect consistent and meaningful

across all studies. Placebo was variable.

Financial news for SAGE dated on 2017-11-09: Sage Therapeutics Reports Brexanolone Achieved Primary Endpoints In Both Phase 3 Trials In Postpartum Depression

Financial news for SAGE dated on 2017-11-02: Sage Therapeutics Q3 EPS \$(1.97) vs \$(1.97) Est., No Sales

Financial news for SAGE dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for SAGE dated on 2017-09-13: Morgan Stanley Healthcare Conference Concludes Today, Presenters Include Ironwood Pharmaceuticals, Sage Therapeutics, Pfizer, TherapeuticsMD, Alnylam, bluebird bio, and Cigna

Financial news for SAGE dated on 2017-09-12: Sage Therapeutics Phase 3 STATUS Trial of Brexalonone in Super-Refractory Status Epilepticus Did Not Meet its Primary Endpoint

Financial news for SAGE dated on 2017-08-09: Stifel Nicolaus Initiates Coverage On Sage Therapeutics with Buy Rating, Announces \$104.00 Price Target

Financial news for SAGE dated on 2017-08-03: Sage Therapeutics Reports Q2 Loss/Share \$(1.88) vs. \$(1.67) Est.

Financial news for SAGE dated on 2017-06-14: Goldman Sachs Global Healthcare Conference Continues Today, Presenters Include: Agilent, Sage Therapeutics, and GW Pharmaceuticals

Financial news for SAGE dated on 2017-05-18: Sage Therapeutics Reports Received Fast Track Designation for SAGE-217 for Treatment of Major Depressive Disorder

Financial news for SAGE dated on 2017-05-16: Needham Initiates Coverage On Sage Therapeutics with Buy Rating, Announces \$82.00 Price Target

Financial news for SAGE dated on 2017-05-09: TheStreet's Adam Feuerstein Tweets '\$SAGE says '217 showed enough "signal of activity" in Parkinson's to move forward. Reading data, I have no idea if that's bullshit or not.'

Financial news for SAGE dated on 2017-05-09: Sage Therapeutics Reports Q1 EPS \$(1.52) vs \$(1.61) Est.

Financial news for SAGE dated on 2017-04-13: Adam Feuerstein TWEEts: "Right now, I don't plan on it taking longer," than 1H, which is why SRSE study results guidance remains same, Jonas told me. \$SAGE

Financial news for SAGE dated on 2017-04-13: Adam Feuerstein Tweets: However, Jonas says still working thru "complexities" of how to unblind/report SRSE data, leaving open possibility it takes more time. \$SAGE

Financial news for SAGE dated on 2017-04-13: Adam Feuerstein Tweets: \$SAGE weak on Cowen note speculating SRSE ph3 results possibly pushed out to Q3. CEO Jonas (to me): No change in timing guidance, still 1H

Financial news for SAGE dated on 2017-03-23: Adam Feuerstein Tweets: \$SAGE Leerink incrementally more bullish on PPD and MMD programs. The "new" bull thesis downplays looming SSRE ph3 outcome.

Financial news for SAGE dated on 2017-02-23: Sage Therapeutics Q4 EPS \$(1.50) vs \$(1.19) Est, No Revenue

Financial news for SAGE dated on 2017-02-22: H.C. Wainwright Downgrades Sage Therapeutics to Neutral

Financial news for SAGE dated on 2017-02-16: SunTrust Says Sage Would Be Good Takeout Target, But Believes An Acquiring Party May Choose To Wait For Top-Line Data Readout From Phase 3 SAGE-547 Trial

Financial news for SAGE dated on 2017-02-16: Sage CEO On Bloomberg Interview Says 'We're on top of everyone's M&A list'

Financial news for SAGE dated on 2017-02-16: Hearing Sage CEO Says Company Has Received Takeover Interest

Financial news for SAGE dated on 2017-02-16: Sage Shares Spiking Higher To High Of ~\$65, Up 8.84% On Day

Financial news for SAGE dated on 2017-02-13: Sage Therapeutics Advances Sage-217 To Phase 2 In Major Depressive Disorder On Positive Signal Of Activity And Tolerability

Financial news for SAGE dated on 2016-12-19: Sage Therapeutics Initiates Phase 2 Clinical Development for SAGE-217 in Mood Disorders

Financial news for SAGE dated on 2016-12-14: Raymond James Upgrades Sage Therapeutics to Strong Buy, Announces \$84.00 Target

Financial news for SAGE dated on 2016-11-14: Stifel Nicolaus Initiates Coverage On Sage Therapeutics, Inc. - Common Stock at Buy, Announces \$90.00

Financial news for SAGE dated on 2016-10-04: Leerink Swann Assumes Sage Therapeutics at Outperform, Announces \$68.00 PT

Financial news for SAGE dated on 2016-09-13: Raymond James Initiates Coverage on Sage Therapeutics at Outperform

Financial news for SAGE dated on 2016-06-29: BMO Capital Initiates Coverage on Sage Therapeutics at Outperform

Financial news for SAGE dated on 2016-06-23: H.C. Wainwright Initiates Coverage on Sage Therapeutics at Buy, Announces \$56.00 PT

Financial news for SAGE dated on 2016-05-24: Chardan Capital Initiates Coverage on Sage Therapeutics at Sell

Financial news for SAGE dated on 2016-05-24: Chardan Capital Initiates Coverage on Sage Therapeutics at Sell, Announces \$18.00 PT

Financial news for SAGE dated on 2016-03-30: Goldman Sachs Initiates Coverage on Sage Therapeutics at Neutral, Announces \$83.00 PT

Financial news for SAGE dated on 2016-03-11: Lake Street Capital Initiates Coverage on Sage Therapeutics at Buy, Announces \$90.00 PT

Financial news for SAGE dated on 2016-01-07: Sage Therapeutics Prices ~3.157M Share Offering @\$47.50/Share

Financial news for SAGE dated on 2015-09-03: SAGE Therapeutics Announces Results from Successful Exploratory Trial in Essential Tremor

Financial news for SAGE dated on 2015-08-06: SAGE Receives Special Protocol Assessment for Phase 3 STAT-Refractory Status EpileUS Trial of SAGE-547 in Superpticus

Financial news for SAGE dated on 2015-05-14: SAGE Therapeutics Achieves 77% Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in SRSE

Financial news for SAGE dated on 2015-04-15: SAGE Therapeutics Prices ~2.285M Share Offering @\$52.50/Share

Financial news for SAGE dated on 2015-01-27: SunTrust Robinson Humphrey Initiates Coverage on Sage Therapeutics at Buy, Announces \$67.00 PT

Financial news for SAGE dated on 2014-11-11: Sage Therapeutics Reports Q3 EPS of \$(0.50) vs \$(0.40) Est

Financial news for SAGE dated on 2014-11-10: SSage Therapeutics Reports SGAE-547 Met Primary, Secondary Efficacy and Safety Endpoints

Financial news for SAGE dated on 2014-11-07: SAGE Therapeutics Announces Six Abstracts Accepted for Poster Presentations at Neuroscience 2014

Financial news for SAGE dated on 2014-09-24: Goldman Sachs Raise Sage Therapeutics

Financial news for SAGE dated on 2014-09-16: SAGE Therapeutics Names Michael F. Cola to Board of Directors

Financial news for SAGE dated on 2014-09-02: SAGE Therapeutics Presents Positive Preclinical Data on SAGE-217

Financial news for SAGE dated on 2014-08-14: Sage Therapeutics Reports Q2 EPS of \$(4.57) Which May Not Compare \$(1.23) Est

Financial news for SAGE dated on 2014-08-12: Leerink Swann Initiates Coverage on Sage Therapeutics at Outperform, Announces \$46.00 PT

Financial news for SAGE dated on 2014-08-12: Goldman Sachs Initiates Coverage on Sage Therapeutics at Neutral, Announces \$38.00 PT

Financial news for SAGE dated on 2014-08-12: Canaccord Genuity Initiates Coverage on Sage Therapeutics at Buy, Announces \$40.00 PT

Financial news for SAGE dated on 2014-08-12: JP Morgan Initiates Coverage on Sage Therapeutics at Overweight, Announces \$42.00 PT

Financial news for SAGE dated on 2014-08-12: Canaccord Genuity Initiates Coverage on Sage Therapeutics at Buy, Announces \$40.00 PT

Financial news for SAGE dated on 2014-07-17: SAGE Therapeutics Prices 5M Share IPO at \$18.00/Share

Financial news for SAGE dated on 2011-10-07: Are Michael Vick and Other Celebrities Involved with a Pump and Dump?

Financial news for SAGE dated on 2011-10-07: Sagebrush Gold Receives Negative Mention by Shortseller